A Systematic Review and Meta-Analysis of the Incidence of Sensorineural Hearing Loss in Head and Neck Cancer Patients Undergoing Chemoradiotherapy Compared to Radiotherapy - Top-Institutions - MDSpire

A Systematic Review and Meta-Analysis of the Incidence of Sensorineural Hearing Loss in Head and Neck Cancer Patients Undergoing Chemoradiotherapy Compared to Radiotherapy

  • By

  • John Bukuru

  • Olivier Sibomana

  • January 14, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Otolaryngology
    • Radiation Oncology
    • Medical Oncology
    • Audiology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Medical Oncology
    • Otolaryngology
    • Audiology

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Otolaryngology
    • Head and Neck Surgery
    • Radiation Oncology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Otolaryngology
    • Radiation Oncology
    • Medical Oncology

  • #5

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Otolaryngology
    • Radiation Oncology
    • Medical Oncology

Original Source(s)

A Systematic Review and Meta-Analysis of the Incidence of Sensorineural Hearing Loss in Head and Neck Cancer Patients Undergoing Chemoradiotherapy Compared to Radiotherapy

  • by John Bukuru, Olivier Sibomana

  • January 14, 2026

Related Content

Proton Therapy in Early-Onset Locally Advanced Rectal Cancer: The Importance of Fertility-Preserving Multimodality Care

The rising incidence and mortality of early-onset colorectal cancer (EOCRC), defined as disease occurring in patients younger than 50, has emerged as a clinically significant trend with implications for screening, diagnosis, and survivorship.

  • by

  • April 28, 2026

  • 5 min
Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients from the DBCG HYPO Randomized Trial

Advanced dose calculation strategies for clinical linear accelerators: a systematic review